{"protocolSection":{"identificationModule":{"nctId":"NCT01763645","orgStudyIdInfo":{"id":"BCD-021-02"},"organization":{"fullName":"Biocad","class":"INDUSTRY"},"briefTitle":"A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer","officialTitle":"International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients"},"statusModule":{"statusVerifiedDate":"2023-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-11","type":"ACTUAL"},"completionDateStruct":{"date":"2014-11","type":"ACTUAL"},"studyFirstSubmitDate":"2012-12-27","studyFirstSubmitQcDate":"2013-01-07","studyFirstPostDateStruct":{"date":"2013-01-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-03-30","resultsFirstSubmitQcDate":"2016-08-31","resultsFirstPostDateStruct":{"date":"2016-10-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2023-04-13","lastUpdatePostDateStruct":{"date":"2024-01-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biocad","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN: bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in inoperable or advanced non-squamous NSCLC patients with pharmacokinetics substudy. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021 compared to Avastin. Also study includes pharmacokinetics assessment."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["NSCLC","bevacizumab","pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":353,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BCD-021 (CISC BIOCAD)","type":"EXPERIMENTAL","description":"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.","interventionNames":["Drug: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Avastin (F. Hoffmann-La Roche Ltd)","type":"ACTIVE_COMPARATOR","description":"In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.","interventionNames":["Drug: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).","armGroupLabels":["Avastin (F. Hoffmann-La Roche Ltd)","BCD-021 (CISC BIOCAD)"],"otherNames":["Avastin","BCD-021"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)","armGroupLabels":["Avastin (F. Hoffmann-La Roche Ltd)","BCD-021 (CISC BIOCAD)"],"otherNames":["Taxacad"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).","armGroupLabels":["Avastin (F. Hoffmann-La Roche Ltd)","BCD-021 (CISC BIOCAD)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","timeFrame":"Day 127"},{"measure":"Area Under the Curve After the First Test Drug Administration","description":"primary outcome measure for pharmacokinetics (PK) substudy","timeFrame":"up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)"}],"secondaryOutcomes":[{"measure":"Complete Response Rate","description":"secondary outcome measure for efficacy evaluation","timeFrame":"Day 127"},{"measure":"Partial Response Rate","description":"secondary outcome measure for efficacy evaluation","timeFrame":"Day 127"},{"measure":"Stabilization Rate","description":"secondary outcome measure for efficacy evaluation","timeFrame":"Day 127"},{"measure":"Progression Rate","description":"secondary outcome measure for efficacy evaluation","timeFrame":"Day 127"},{"measure":"Occurrence of Anti-bevacizumab Antibodies","description":"Secondary outcome measure for immunogenicity assessment","timeFrame":"Day 1 (before the drug administration), Day 15, 64 and 127"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent;\n* Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous NSCLC (mixed cancer types should be classified according to the prevalent cell type);\n* IIIb or IV stage of NSCLC (TNM classification version 6);\n* Age ≥ 18 years and age ≤ 75 years (both inclusive);\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not declining within 2 weeks prior to the first dose of investigational product);\n* Life expectancy - 12 weeks or more from the moment of randomization;\n* Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed with CT slice thickness not more than 5 mm), as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites, pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as only lesion;\n* Patients should be able to follow the Protocol procedures (according to Investigator's assessment);\n* Patients must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 6 months after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization, or patients who are postmenopausal (documented) for the past 2 years. Reliable contraceptive measures include two methods of contraception, including one barrier method\n\nExclusion Criteria:\n\n* Squamous NSCLC;\n* Proven coagulopathy, clinically significant hemorrhage in the past including nasal hemorrhage;\n* absolute neutrophil count \\<1500/mm3;\n* Platelets \\<100 000/mm3;\n* Hemoglobin \\< 90 g/L;\n* Creatinine level ≥1.5 mg/dL;\n* Bilirubin level ≥1.5 × upper limit of normal (ULN);\n* Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels ≥2.5 × ULN (≥5 × ULN for patients with liver metastases);\n* Alkaline phosphatase level ≥5 × ULN;\n* Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day), nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment with these drugs less than 1 month before entering the study;\n* Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medical correction methods (low salt diet, physical exercise);\n* Any previous anticancer therapy (chemotherapy, radiation therapy , surgery etc.) of metastatic NSCLC;\n* Radiation or hormone therapy within 21 days prior to randomization;\n* Major surgery 28 days before inclusion into the study;\n* Previous antiangiogenic therapy;\n* Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine, ranitidine) or excipients of investigational products;\n* NSCLC metastases in central nervous system excluding metastases non-progressing without glucocorticosteroids within 4 weeks before inclusion into the trial;\n* Cardiovascular system pathology (CHF stage III-IV according to New York Heart Association (NYHA) classification);\n* Pregnancy or lactation;\n* Conditions limiting patient's adherence to Protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);\n* Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0;\n* Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;\n* Any other concomitant cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;\n* Acute or active chronic infections;\n* Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections;\n* Obstacles in intravenous administration of study drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yulia Linkova, MD, PhD","affiliation":"Director of Clinical Development Department, BIOCAD","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Brest Regional Clinical Dispensary","city":"Brest","country":"Belarus","geoPoint":{"lat":52.10894,"lon":23.71749}},{"facility":"Grodno Regional Clinical Hospital","city":"Grodno","country":"Belarus","geoPoint":{"lat":53.62865,"lon":23.8942}},{"facility":"Gomel Regional Clinical Oncology Dispensary","city":"Homyel","country":"Belarus","geoPoint":{"lat":52.4345,"lon":30.9754}},{"facility":"Vitebsk Regional Clinical Oncology Dispensary","city":"Vitebsk","country":"Belarus","geoPoint":{"lat":55.1904,"lon":30.2049}},{"facility":"HCG Bangalore Institute of Oncology","city":"Bangalore","zip":"560027","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"M.S.Ramaiah Memorial Hospital","city":"Bangalore","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Narayana Hrudayalaya Hospitals","city":"Bangalore","zip":"560099","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Arkhangelsk District Clinical Oncology Dispensary","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Non-governmental Healthcare Institution \"Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways\"","city":"Chelyabinsk","zip":"454000","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"State-financed Health Institution \"Chelyabinsk Region Clinical Oncology Dispansary\"","city":"Chelyabinsk","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"State Healthcare Facility \"Kursk Regional Oncology Dispensary\"","city":"Kursk","zip":"305035","country":"Russia","geoPoint":{"lat":51.72689,"lon":36.18457}},{"facility":"Institution of Russian Academy of Medical Sciences \"Russian Cancer Research Center named after N.N. Blokhin\"","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Federal State Institution \"Moscow Institute of Cancer Research named after P.A. Hertsen\" Ministry of Health of Russian Federation","city":"Moscow","zip":"194044","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"State Health Institution of Moscow \"Moscow City Oncology Hospital #62 of Moscow Board of Health\"","city":"Moscow Region","zip":"143423","country":"Russia"},{"facility":"Murmansk Regional Oncology Dispensary","city":"Murmansk","zip":"183047","country":"Russia","geoPoint":{"lat":68.96778,"lon":33.09922}},{"facility":"Nizhny Novgorod Region State Budgetary Healthcare Facility \"Clinical Diagnostics Center\"","city":"Nizhny Novgorod","zip":"603006","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"State Healthcare Facility \"Nizhny Novgorod Regional Oncology Dispensary\"","city":"Nizhny Novgorod","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"City Clinical Hospital №1","city":"Novosibirsk","zip":"630047","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"Regional State Health Institution \"Orlov Oncology Dispansary\"","city":"Oryol","zip":"302020","country":"Russia","geoPoint":{"lat":52.96879,"lon":36.0791}},{"facility":"State Health Institution \"Region Oncology Dispansary\"","city":"Penza","zip":"440071","country":"Russia","geoPoint":{"lat":53.19568,"lon":45.01075}},{"facility":"Perm Region Oncology Dispensary","city":"Perm","zip":"614066","country":"Russia","geoPoint":{"lat":58.01046,"lon":56.25017}},{"facility":"Federal Government Budgetary Institution \"Rostov Institute of Cancer Research\" of Ministry of Health of Russian Federation","city":"Rostov-on-Don","zip":"314019","country":"Russia","geoPoint":{"lat":47.21997,"lon":39.70769}},{"facility":"Saint Petersburg City Clinical Oncology Center","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"St. Petersburg State Medical University n.a. I. P. Pavlov","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"N.N.Petrov Oncology Research Center","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"St. Petersburg Research and Practice Center for Secondary Care in Oncology","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Military Medical Academy named after S.M. Kirov","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Russian scientific center of radiology and surgery technologies","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"State-financed Health Institution \"Samara Region Clinical Oncology Dispansary\"","city":"Samara","zip":"443031","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Oncology Dispensary 2","city":"Sochi","zip":"354057","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"State-financed Health Institution \"Stavropol Region Clinical Oncology Dispansary\"","city":"Stavropol","zip":"355047","country":"Russia","geoPoint":{"lat":45.03442,"lon":41.9642}},{"facility":"Volgograd District Oncology Dispensary №1","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Volgograd Regional Oncology Dispensary №3","city":"Volgograd","zip":"404130","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"State Health Institution \"Voronezh Region Clinical Oncology Dispansary\"","city":"Voronezh","zip":"394000","country":"Russia","geoPoint":{"lat":51.66833,"lon":39.19204}},{"facility":"Donetsk City Oncology Dispensary","city":"Donetsk","country":"Ukraine","geoPoint":{"lat":48.023,"lon":37.80224}},{"facility":"Donetsk Regional Antitumor Center","city":"Donetsk","country":"Ukraine","geoPoint":{"lat":48.023,"lon":37.80224}},{"facility":"Kharkiv Regional Clinical Oncology Center","city":"Kharkiv","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Kryvyi Rih Oncology Dispensary","city":"Kryvyi Rih","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"Lviv State Regional Cancer Diagnostic and Treatment Center","city":"Lviv","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"City Hospital № 2","city":"Makiivka","country":"Ukraine","geoPoint":{"lat":48.04782,"lon":37.92576}},{"facility":"Poltava Regional Clinical Oncology Dispensary","city":"Poltava","country":"Ukraine","geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"Zakarpatskyi Clinical Oncology Dispensary","city":"Uzhhorod","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Vinnytsia Regional Clinical Oncology Dispensary","city":"Vinnytsia","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Zaporizhia Regional Clinical Oncology Dispensary","city":"Zaporizhia","country":"Ukraine"}]},"referencesModule":{"references":[{"pmid":"35105329","type":"DERIVED","citation":"Stroyakovskiy DL, Fadeeva NV, Matrosova MP, Shelepen KG, Adamchuk GA, Roy B, Nagarkar R, Kalloli M, Zhuravleva D, Voevodin GD, Shustova MS, Kryukov F. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer. 2022 Feb 1;22(1):129. doi: 10.1186/s12885-022-09243-7."}],"seeAlsoLinks":[{"label":"Stroyakovskiy, D.L., Fadeeva, N.V., Matrosova, M.P. et al. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer 22, 129 (2022). https://doi.org/10.1186/s12885-022-09243-7","url":"https://doi.org/10.1186/s12885-022-09243-7"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"343 of 353 patients received at least one dose of the study drug/comparator. 10 patients discontinued the study without receiving a single dose of the study drug/comparator. The safety analysis included all data from all randomized subjects who received at least one dose of study therapy, 2 of 343 patients were excluded from the efficacy analysis due to screening failure (1 in each group), n= 341.","groups":[{"id":"FG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"FG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"211"},{"groupId":"FG001","numSubjects":"142"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"137"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Completed the study according the protocol.","numSubjects":"87"},{"groupId":"FG001","comment":"Completed the study according the protocol.","numSubjects":"56"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"124"},{"groupId":"FG001","numSubjects":"86"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Patients who received at least 1 dose of the study drug","groups":[{"id":"BG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"BG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel.\n\nAvastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1.\n\nPaclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"343"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"57.79","spread":"8.88"},{"groupId":"BG001","value":"58.67","spread":"8.33"},{"groupId":"BG002","value":"58.23","spread":"8.61"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"2 of 343 participants were excluded from the analysis due to screening failure (1 in each group). 341 participants were analyzed (205 participants in BCD-021 group and 136 participants in Avastin group)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"341"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"142"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"230"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"111"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","populationDescription":"The efficacy analysis included only those patients who received at least one dose of BCD-021 or Avastin®, and in whom it was possible to assess the response to therapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participans","timeFrame":"Day 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel.\n\nAvastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1.\n\nPaclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.63"},{"groupId":"OG001","value":"33.82"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve After the First Test Drug Administration","description":"primary outcome measure for pharmacokinetics (PK) substudy","populationDescription":"Patients who received one dose of study drug and after 504 hours after injection had missed \\<= 1 blood sample collection to analyze pharmacokinetics.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"(ng/ml)*hour","timeFrame":"up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26951463","lowerLimit":"6114172.35","upperLimit":"68355846"},{"groupId":"OG001","value":"23970112.875","lowerLimit":"8216733.75","upperLimit":"80859445.5"}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"secondary outcome measure for efficacy evaluation","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"Day 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","lowerLimit":"0.33","upperLimit":"9.77"},{"groupId":"OG001","value":"1.79","lowerLimit":"0.32","upperLimit":"9.45"}]}]}]},{"type":"SECONDARY","title":"Partial Response Rate","description":"secondary outcome measure for efficacy evaluation","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"Day 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.74","lowerLimit":"28.68","upperLimit":"54.03"},{"groupId":"OG001","value":"37.50","lowerLimit":"26.01","upperLimit":"50.59"}]}]}]},{"type":"SECONDARY","title":"Stabilization Rate","description":"secondary outcome measure for efficacy evaluation","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"Day 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.85","lowerLimit":"38.85","upperLimit":"64.60"},{"groupId":"OG001","value":"51.79","lowerLimit":"39.01","upperLimit":"64.34"}]}]}]},{"type":"SECONDARY","title":"Progression Rate","description":"secondary outcome measure for efficacy evaluation","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"Day 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","lowerLimit":"1.91","upperLimit":"15.11"},{"groupId":"OG001","value":"8.93","lowerLimit":"3.88","upperLimit":"19.26"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-bevacizumab Antibodies","description":"Secondary outcome measure for immunogenicity assessment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"Day 1 (before the drug administration), Day 15, 64 and 127","groups":[{"id":"OG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."},{"id":"OG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47"},{"groupId":"OG001","value":"1.52"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"6 therapy cycles","description":"The safety analysis included all subjects who received at least one dose of BCD-021 or Avastin® (n = 343).","eventGroups":[{"id":"EG000","title":"BCD-021 (CISC BIOCAD)","description":"In this arm patients received 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.\n\nData on adverse events was collected from date of signing informed consent up to 18 weeks after first injection of study drug.","deathsNumAffected":14,"deathsNumAtRisk":206,"seriousNumAffected":36,"seriousNumAtRisk":206,"otherNumAffected":206,"otherNumAtRisk":206},{"id":"EG001","title":"Avastin (F. Hoffmann-La Roche Ltd)","description":"In this arm patients received 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin was administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1.\n\nPaclitaxel was administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.\n\nData on adverse events was collected from date of signing informed consent up to 18 weeks after first injection of study drug.","deathsNumAffected":8,"deathsNumAtRisk":137,"seriousNumAffected":20,"seriousNumAtRisk":137,"otherNumAffected":137,"otherNumAtRisk":137}],"seriousEvents":[{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":206},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Deafness neurosensory","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Fournier's gangrene","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Scrotal infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Death","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":206},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Disease progression","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Poisoning","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":206},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":206},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":104,"numAffected":104,"numAtRisk":206},{"groupId":"EG001","numEvents":78,"numAffected":78,"numAtRisk":137}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":60,"numAtRisk":206},{"groupId":"EG001","numEvents":42,"numAffected":42,"numAtRisk":137}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":45,"numAtRisk":206},{"groupId":"EG001","numEvents":37,"numAffected":37,"numAtRisk":137}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":42,"numAtRisk":206},{"groupId":"EG001","numEvents":39,"numAffected":39,"numAtRisk":137}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":206},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":137}]},{"term":"Neutrophilia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":206},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":137}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":206},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":137}]},{"term":"Erythropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":206},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":137}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":206},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":137}]},{"term":"Lymphocytosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":206},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":137}]},{"term":"Polycythaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":206},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":206},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":137}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":206},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":137}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":206},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":137}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":206},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":137}]},{"term":"Blood uric acid increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":206},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":137}]},{"term":"White blood cell count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":206},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":137}]},{"term":"Blood creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":206},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":137}]},{"term":"Blood pressure systolic increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":206},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":137}]},{"term":"Blood urea increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":206},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":137}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":206},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":137}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":206},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":137}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":206},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":137}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":53,"numAtRisk":206},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":137}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":39,"numAtRisk":206},{"groupId":"EG001","numEvents":34,"numAffected":34,"numAtRisk":137}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":206},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":137}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":206},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":137}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":206},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":137}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":206},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":137}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":206},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":137}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":206},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":137}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":206},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":137}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":206},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":137}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Feder Krykov","organization":"BIOCAD","email":"kryukov@biocad.ru","phone":"+7 (812) 380 4933","phoneExt":"8552"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}